Ionis Pharmaceuticals (IONS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS)

IONS 81.55

-2.0%

Jan 8 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: bob zagorin	3/1/2011 12:13:57 PM
	Read Replies (1) of 4676

Needham Company Maintains a 'Hold' on ISIS Pharmaceuticals (ISIS); Strong Focus on Mipomersen Next Steps by Genzyme, Steady Progress of Early-Stage Pipeline Needham Company maintains a 'Hold' on ISIS Pharmaceuticals (NASDAQ: ISIS). Needham analyst says, "Yesterday, ISIS reviewed 4Q10 results and expected 2011 progress. We believe that mipomersen regulatory and commercial risks remain, and we note an early-stage pipeline beyond the advanced mipomersen compound." "Faster than expected regulatory timeline for mipomersen or positive progress of the clinical trials underway for other products may provide an upside to our valuation thesis. In the long-term, we believe that Isis broad antisense platform and 24 pipeline candidates under development by ISIS and/or its brand name biotech/Pharma partners may drive the valuation theme." For more ratings news on ISIS Pharmaceuticals click here and for the rating history of ISIS Pharmaceuticals click here. Shares of ISIS Pharmaceuticals closed at $9.12 yesterday, with a 52 week range of $7.59-$11.43.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next